The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).
The main question, it aims to answer is:
Does abnormal regional ventilation could predict HFNC or NIV failure?
Age of ≥ 18 years
Using NIV or HFNC anywhere in the hospital
Chronic CO2 retention
Neuromuscular disorder
Requiring home NIV (CPAP or BIPAP)
Tracheostomy
Patient who is using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) to either prevent 1. intubation in the context of acute hypoxemic respiratory failure or 2. reintubation in the context of high risk group of extubation.
Cohort
Prospective
Not listed
Difference in regional ventilation distribution (%)
The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure.
Diaphragm or parasternal intercostal muscle thickening fraction
To assess ultrasound measurement of inspiratory muscle activity when using HFNC or NIV to predict a device failure.
Rapid shallow breathing index (RSBI) in mL/breaths/min
To assess non-invasive respiratory - rapid shallow breathing index (RSBI) derived from NIV to predict a device failure.
Respiratory drive using negative airway pressure generated during the first 100 millisecond (P0.1)
To assess respiratory drive - using negative airway pressure generated during the first 100 millisecond (P0.1) in cmH2O to predict device failure.
Respiratory effort using end-expiratory airway occlusion pressure (ΔPocc)
To assess respiratory effort using end-expiratory airway occlusion pressure (ΔPocc) in cmH2O to predict device failure
Click on the lead sponsor to view all of their trials.
